Colorectal cancer(CRC)is a leading cause of human mortality worldwide.As conventional anticancer therapy not always being effective,there is growing interest in innovative“drug-free”cancer treatments or intervention...Colorectal cancer(CRC)is a leading cause of human mortality worldwide.As conventional anticancer therapy not always being effective,there is growing interest in innovative“drug-free”cancer treatments or interventions that improve the efficacy of established therapy.CRC is associated with microbiome alterations,a process known as dysbiosis that involves depletion and/or enrichment of particular gut bacterial species and their metabolic functions.Supplementing patient treatment with traditional probiotics(with or without prebiotics),nextgeneration probiotics(NGP),or postbiotics represents a potentially effective and accessible complementary anticancer strategy by restoring gut microbiota composition and/or by signaling to the host.In this capacity,restoration of the gut microbiota in cancer patients can stabilize and enhance intestinal barrier function,as well as promote anticarcinogenic,anti-inflammatory,antimutagenic or other biologically important biochemical pathways that show high specificity towards tumor cells.Potential benefits of traditional probiotics,NGP,and postbiotics include modulating gut microbiota composition and function,as well as the host inflammatory response.Their application in CRC prevention is highlighted in this review,where we consider supportive in vitro,animal,and clinical studies.Based on emerging research,NGP and postbiotics hold promise in establishing innovative treatments for CRC by conferring physiological functions via the production of dominant natural products and metabolites that provide new host-microbiota signals to combat CRC.Although favorable results have been reported,further investigations focusing on strain and dose specificity are required to ensure the efficacy and safety of traditional probiotics,NGP,and postbiotics in CRC prevention and treatment.展开更多
The gut microbiota is important in the development and progression of metabolic illnesses such type 2 diabetes,cardiovascular disease(CVD),and obesity.This diverse community of microorganisms controls a variety of phy...The gut microbiota is important in the development and progression of metabolic illnesses such type 2 diabetes,cardiovascular disease(CVD),and obesity.This diverse community of microorganisms controls a variety of physiological functions,including metabolism,inflammation,and immune response.Understanding these interactions has resulted in novel therapeutic options,including microbiome supplementation.The gut microbiome is extremely susceptible to dietary changes,which can alter its makeup and function,influencing metabolite synthesis that affects host health.Certain metabolites,such as butyrate and propionate,have been proven to protect against metabolic illnesses,whereas trimethylamine has been linked to CVD.Prebiotics,probiotics,synbiotics,and postbiotics are being investigated by researchers as ways to change the gut microbiome and boost metabolic health.Despite advances in therapy and lifestyle adjustments,the prevalence of metabolic syndrome is increasing,emphasizing the need for new medicines.展开更多
基金Supported by Scientific Grant Agency of the Ministry of Education of Slovak Republic and Academy of Sciences VEGA,No.1/0393/20the Operational Program Integrated Infrastructure Within the Project:Demand-Driven Research for the Sustainable and Innovative Food,Co-financed by the European Regional Development Fund,No.Drive4SIFood 313011V336.
文摘Colorectal cancer(CRC)is a leading cause of human mortality worldwide.As conventional anticancer therapy not always being effective,there is growing interest in innovative“drug-free”cancer treatments or interventions that improve the efficacy of established therapy.CRC is associated with microbiome alterations,a process known as dysbiosis that involves depletion and/or enrichment of particular gut bacterial species and their metabolic functions.Supplementing patient treatment with traditional probiotics(with or without prebiotics),nextgeneration probiotics(NGP),or postbiotics represents a potentially effective and accessible complementary anticancer strategy by restoring gut microbiota composition and/or by signaling to the host.In this capacity,restoration of the gut microbiota in cancer patients can stabilize and enhance intestinal barrier function,as well as promote anticarcinogenic,anti-inflammatory,antimutagenic or other biologically important biochemical pathways that show high specificity towards tumor cells.Potential benefits of traditional probiotics,NGP,and postbiotics include modulating gut microbiota composition and function,as well as the host inflammatory response.Their application in CRC prevention is highlighted in this review,where we consider supportive in vitro,animal,and clinical studies.Based on emerging research,NGP and postbiotics hold promise in establishing innovative treatments for CRC by conferring physiological functions via the production of dominant natural products and metabolites that provide new host-microbiota signals to combat CRC.Although favorable results have been reported,further investigations focusing on strain and dose specificity are required to ensure the efficacy and safety of traditional probiotics,NGP,and postbiotics in CRC prevention and treatment.
文摘The gut microbiota is important in the development and progression of metabolic illnesses such type 2 diabetes,cardiovascular disease(CVD),and obesity.This diverse community of microorganisms controls a variety of physiological functions,including metabolism,inflammation,and immune response.Understanding these interactions has resulted in novel therapeutic options,including microbiome supplementation.The gut microbiome is extremely susceptible to dietary changes,which can alter its makeup and function,influencing metabolite synthesis that affects host health.Certain metabolites,such as butyrate and propionate,have been proven to protect against metabolic illnesses,whereas trimethylamine has been linked to CVD.Prebiotics,probiotics,synbiotics,and postbiotics are being investigated by researchers as ways to change the gut microbiome and boost metabolic health.Despite advances in therapy and lifestyle adjustments,the prevalence of metabolic syndrome is increasing,emphasizing the need for new medicines.
